Completed PHASE3 INTERVENTIONAL 3-arm NCT00229424

Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

Sponsor: Taiho Pharmaceutical Co., Ltd.

Interventions Famotidine Lafutidine Placebo

Updated 5 times since 2017 Last updated: Jul 6, 2011 Started: Apr 30, 2005 Primary completion: Oct 31, 2006 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00229424, this PHASE3 trial focuses on Gastroesophageal Reflux and remains completed. Sponsored by Taiho Pharmaceutical Co., Ltd., it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Taiho Pharmaceutical Co., Ltd.
UCB Pharma

Data source: Taiho Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• 1-1, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan